18F-FAPI-42 PET/MRI in the Evaluation of Glioma Recurrence
The diagnostic efficacy of 18 F-FAPI-42 PET for glioma recurrence is comparable to 11 C-MET PET, and its specificity superior to CE-MRI. 18 F-FAPI-42 PET has a high TBR and advantages in delineating glioma boundaries, which may provide valuable information for therapeutic decision-making.
Authors
- Jianghua Ran
- Jiaying Li (ORCID: https://orcid.org/0009-0004-8903-8239)
- Guangcheng Luo (ORCID: https://orcid.org/0000-0001-9928-4426)
- Wenyu Gong (ORCID: https://orcid.org/0000-0001-6806-8974)
- Renxiang Xia
- Jifeng Sun (ORCID: https://orcid.org/0000-0003-0106-528X)
- Long He (ORCID: https://orcid.org/0009-0001-3488-9229)
- Xiao Chen (ORCID: https://orcid.org/0000-0003-2464-4313)
- Yi Luo (ORCID: https://orcid.org/0009-0000-9231-176X)
- Xin Li (ORCID: https://orcid.org/0009-0002-0724-7738)
Institutions
- Army Medical University (CN)
- Daping Hospital (CN)
- Chongqing Emergency Medical Center (CN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1097/rlu.0000000000006220
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00